Business Context and Reporting Period
This Form 8-K is filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) on November 29, 2016. The report addresses a regulatory notice regarding the company's stock listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance: the minimum bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days.
Material Changes
- Listing Non-Compliance: The Company received a notice from Nasdaq stating it is not in compliance with Marketplace Rule 5550(a)(2) due to the sustained low stock price.
- Grace Period: The Company has been granted 180 calendar days (until May 30, 2017) to regain compliance.
- Compliance Requirement: To remain listed, the closing bid price must meet or exceed $1.00 per share for at least ten consecutive business days within the grace period.
Outlook, Risks, and Contingencies
- Delisting Risk: If the Company fails to regain compliance by May 30, 2017, or is not granted an extension, Nasdaq will notify the Company that its securities will be subject to delisting.
- Extension Possibility: The Company may be eligible for additional time if it meets other listing standards (e.g., market value of publicly held shares) and intends to cure the deficiency, potentially via a reverse stock split.
- Appeal Rights: The Company may appeal a delisting determination to a Hearings Panel. During any appeal, shares will continue to trade on the Nasdaq Capital Market.
- Immediate Impact: The notification has no immediate effect on the listing or trading of the stock.
Investor Verification Checklist
- Verify the current trading price of Catalyst Biosciences, Inc. stock to assess proximity to the $1.00 threshold.
- Monitor future announcements regarding the Company's plan to regain compliance (e.g., reverse stock split proposals).
- Check for any subsequent filings indicating an appeal to a Hearings Panel or an extension request.
- Confirm the Company's market value of publicly held shares to determine eligibility for a second compliance period.